Femasys Inc (FEMY) Actualités

Femasys Announces Infertility Clinic Customers from Coast to Coast

ATLANTA, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company...

Form 8-K - Current report

Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market

ATLANTA, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company...

Form 8-K - Current report

Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check

ATLANTA, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company...

Femasys to Exhibit at The Canadian Fertility and Andrology Society’s 70th Annual Meeting

ATLANTA, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company...

Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference

ATLANTA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company...

Form 8-K - Current report

Form 8-K - Current report

Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution

ATLANTA, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused...

Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters

ATLANTA, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update

ATLANTA, Aug. 08, 2024 (GLOBE NEWSWIRE) --  Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused...

Form 4 - Statement of changes in beneficial ownership of securities